Terns Pharmaceuticals to Present at Upcoming Investor Conferences
May 24 2023 - 4:05PM
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq:
TERN), a clinical-stage biopharmaceutical company developing a
portfolio of small-molecule product candidates to address serious
diseases, including oncology, non-alcoholic steatohepatitis (NASH)
and obesity, today announced that management will be participating
in a fireside chat at the TD Cowen 4th Annual Oncology Innovation
Summit on Wednesday, May 31, 2023 at 3:00 p.m. ET. Terns management
will also present at the 2023 Jefferies Healthcare Conference on
Thursday, June 8, 2023 at 12:30 p.m. ET.
A live webcast of each event will be available on the investor
relations page of the Terns Pharmaceuticals website at
http://ir.ternspharma.com. A replay of the webcasts will be
archived on Terns’ website for at least 30 days following the
presentations.
About Terns PharmaceuticalsTerns
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
developing a portfolio of small-molecule product candidates to
address serious diseases, including oncology, NASH and obesity.
Terns’ pipeline includes two clinical stage development programs
including an allosteric BCR-ABL inhibitor and a THR-β agonist (+/-
an FXR agonist), and preclinical small-molecule GLP-1 receptor
agonist and GIPR modulator programs. For more information, please
visit: www.ternspharma.com.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public
Relationsmedia@ternspharma.com
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Apr 2024 to May 2024
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From May 2023 to May 2024